Ultragenyx Pharmaceutical Inc. (RARE) stock
RARENasdaqPharmaceutical PreparationsFiscal year ends December 31
$16.70+0.80 (+5.03%)
Close on Nov 17, 2026Market cap $1.65BP/E –Yield –
Ultragenyx Pharmaceutical gross margin
Gross margin is gross profit as a percentage of revenue.
Ultragenyx Pharmaceutical's gross margin for the twelve months ending Jun 30, 2019 was 97.2%. For fiscal 2018 it was 97.8%, against 100.0% the year before.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | 97.8% | −2.2 |
| FY2017 | Dec 31, 2017 | 100.0% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2019 | Jun 30, 2019 | 96.8% | −2.1 |
| Q1 FY2019 | Mar 31, 2019 | 97.5% | −0.4 |
| Q4 FY2018 | Dec 31, 2018 | 96.9% | – |
| Q3 FY2018 | Sep 30, 2018 | 97.7% | – |
| Q2 FY2018 | Jun 30, 2018 | 98.9% | – |
| Q1 FY2018 | Mar 31, 2018 | 97.9% | – |
See a number that looks wrong?